From bone resorption inhibitor to neuroprotective drug: The effects of bisphosphonates

Abstract Bisphophonates, a commonly prescribed class of drug for osteoporosis, have revealed promising pharmacological benefits for neurological conditions as they share common pathological features. Bisphophonates inhibit protein prenylation in the mevalonate pathway – associated with inflammation and immune response – and are thought to be disrupted in neurodegenerative diseases. Although the molecular evidence to support the bisphophonates’ neuroprotective effects remains elusive, their potential immunomodulatory role in the Central Nervous System (CNS) has been described both in pre-clinical and clinical studies. Since the drug is well-tolerated and readily available, there has been increased interest in its repurposing for the described conditions.

• Publication year

  2019

• Venue

  Pharmacological Reports

• Publication date

  2019-03-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.PHAREP.2019.03.010PMID 31207431
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alendronate treatment induces IL-1B expression and apoptosis in glioblastoma cell line

  2018cited by this paper
• Bisphosphonates: Future perspective for neurological disorders

  2018cited by this paper
• Primary brain calcification in patients undergoing treatment with the biphosphanate alendronate

  2016cited by this paper
• Generation of mutation hotspots in ageing bacterial colonies

  2016cited by this paper
• Neuroprotective Effects of Etidronate and 2,3,3-Trisphosphonate Against Glutamate-Induced Toxicity in PC12 Cells

  2015cited by this paper
• An update on primary familial brain calcification.

  2013cited by this paper
• Increased risk of dementia in patients with osteoporosis: a population-based retrospective cohort analysis

  2013cited by this paper
• Bisphosphonates for osteoporosis--where do we go from here?

  2012cited by this paper
• Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents

  2012cited by this paper
• Microglia-mediated IGF-I neuroprotection in the rd10 mouse model of retinitis pigmentosa.

  2011cited by this paper
• Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases.

  2007cited by this paper
• Regulation of Cytokine Receptor Signaling by Nuclear Hormone Receptors: A New Paradigm for Receptor Interaction

  2004cited by this paper
• Bisphosphonates: mechanisms of action

  1998cited by this paper
• Functional improvement in a patient with cerebral calcinosis using a bisphosphonate

  1998cited by this paper
• Bisphosphonates: mechanisms of action.

  1996cited by this paper

• No genetic causal association between Alzheimer’s disease and osteoporosis: A bidirectional two-sample Mendelian randomization study

  2023cites this paper
• Bisphosphonate-Modified Functional Supramolecular Hydrogel Promotes Periodontal Bone Regeneration by Osteoclast Inhibition.

  2023cites this paper
• Bone Mineral Density and the Risk of Parkinson's Disease in Postmenopausal Women

  2023cites this paper
• Astrocyte Dysregulation and Calcium Ion Imbalance May Link the Development of Osteoporosis and Alzheimer’s Disease

  2022cites this paper